RCT has assembled an experienced, multidisciplinary team with deep and broad expertise spanning all aspects from early research and development to commercialization of novel cell therapy.
Dr. Baskar MSc(Micrbio), M.Phil, PhD.
Chief Scientist
Head of Production/Research Department
Dr. Sellamuthu MSc (Biochemistry), M.Tech (Bio-Technology), PhD
Chief Scientist
Head of Production / Research Department
Ms. Phang Su Wen M.Sc (Biology)
Production Manager
Production Department
Ms. Agila M.Sc (Biology)
Quality Control Manager
Head of Quality Control Department
Muhammad Hariz Zafran Bin Zainal Abidin
Bachelor Degree in Science (Hons) Biology
Quality Control Executive
Ms. Nadiah M.Sc (Life Science)
Product Assistant & Research officer
Research Department
Dr. Sellamuthu is Chief Technology Officer Regen Cell Tech Sdn Bhd (RCT). He has broad and deep industry experience developing Cell and Gene Therapy (CGT) products. He brings extensive and pioneering expertise in the product development, manufacturing and supply of cell-based therapies and associated analytics.
Dr. Sellamuthu has several years of biotech industry experience, holding positions in Technical Development, manufacturing, and Quality in well established companies. He comes to Regen cell tech from previous company where he was Senior Advisor, Cell and Gene Therapy Manufacturing. In his current position, he is instrumental in developing and implementing the strategy for CGT manufacturing and controls the organization. To strengthen the Regenerative medicine, he and his team are currently working on the production of GMP grade Mesenchymal Stem Cell from various sources of adult organs (Umbilical cord, Bone marrow and Adipose tissue) for life threatening diseases. His primary mission is to develop an effective therapeutic approach for various unsolved life threatening diseased including osteoarthritis, frailty, chronic kidney disease and GvHD.
Dr. Sellamuthu received his doctorate degree for his work in state of stem cell in skeletal muscle regeneration from University of Madras at Chennai, India in 2014. While his doctoral research, he was actively collaborated with University of Utah (USA) to conduct research in the area of stem cell biology for skeletal/Cardiac muscle regeneration. He has participated in numerous workshops and advanced courses in the area of aging and stem cell biology. He has authored in many publications related to aging physiology and stem cell biology.
As a stem cell scientist, he and his team are currently working on the production of GMP-grade Mesenchymal Stem Cells from adult tissue sources such as umbilical cord, bone marrow, and adipose tissue for life-threatening diseases.
His primary mission is to develop effective anti-cancer therapeutic approaches to enhance immune response, regress or control tumor growth, and stabilize or eradicate disease.
DR. SELLAMUTHU, MSc (Biochemistry), M.Tech (Bio-Technology) PhD (Regenerative medicine)
Dr. Sellamuthu is the Chief Technology Officer of Regen Cell Tech Sdn Bhd. He brings extensive expertise in cell and gene therapy product development, manufacturing, and analytics.
He has held senior positions in technical development, manufacturing, and quality across well-established biotech companies. Prior to Regen Cell Tech, he served as Senior Advisor in Cell and Gene Therapy Manufacturing, where he was instrumental in developing CGT manufacturing strategies.
He has collaborated internationally, including with the University of Utah (USA), and continues to contribute significantly to regenerative medicine research.
Qualification
Bachelor Degree in Science (Hons) Biology
Experience
Muhammad Hariz Zafran Bin Zainal Abidin is a Quality Control Executive at Regen Celltechs Sdn Bhd, a fresh cell manufacturing laboratory based in Malaysia. With four years of industry experience, he is skilled in Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Distribution Practices (GDP), supply chain coordination, and quality control operations.
He has a strong background in maintaining quality management systems and ensuring full compliance with regulatory requirements. He is well-versed in conducting thorough inspections of raw materials, in-process products, and finished goods to ensure alignment with both company standards and regulatory requirements.
Qualification
Bachelor in Biotechnology (Hons.), minor in Drug Discovery
Master in Science
Professional Experience
Phang Su Wen serves as the Head of Production, overseeing all manufacturing operations within a cGMP-compliant stem cell therapy facility while ensuring strict adherence to regulatory and quality standards.
With a Master’s degree in Science and over six years of experience in stem cell bioprocessing, she specializes in cell expansion, characterization, and aseptic manufacturing within controlled environments.
Her expertise includes process development, scale-up, and technology transfer from research and development to full-scale production, with a strong emphasis on product consistency, sterility assurance, and batch record integrity.
She also leads validation activities, equipment qualification, and documentation processes, ensuring robust and regulatory-compliant manufacturing of advanced cell-based therapeutic products.
Position
Quality Control Cum Assistant Production
Qualification
Professional Experience
Agilandeswarie Kavin Selvam has over three years of experience working in GMP-certified cleanroom environments, consistently maintaining high standards of quality, safety, and regulatory compliance.
Her technical background includes three years of hands-on experience in Mesenchymal Stem Cell (MSC) production and six months in NK (Natural Killer) exosome research and manufacturing.
She also brings strong Quality Assurance expertise, with a focus on documentation control, SOP development, and supply chain coordination to support smooth, compliant, and efficient production operations.
Academic Qualifications
Professional Experience
The individual has experience as an Assistant Production staff member at RegenCell Techs Sdn. Bhd., supporting GMP-compliant manufacturing activities including in-process operations, product packaging, labelling, documentation, and regulatory compliance.
The technical skill set includes cell culture and molecular biology techniques such as PCR and DNA extraction, along with laboratory documentation, data analysis, and equipment maintenance in regulated laboratory environments.
Proficiency includes the use of Microsoft Office and GraphPad Prism for data management, analysis, and scientific reporting. Through academic and research involvement, experience was gained in method validation, data interpretation, and preparation of scientific reports, including contributions to published work and conference presentations.
The professional profile is characterized by strong organizational skills, attention to detail, commitment to accuracy and quality, and effective communication abilities in both English and Bahasa Melayu.
Dr. Baskar obtained his Doctorate from Bharathiar University, India. Prior to fully dedicating his career to immunology and stem cell–based regenerative medicine, he built a strong research foundation by working at reputed institutions, including the Indo-Japan Research Institute—a Japanese firm in India extensively involved in research utilizing human adult cells from various tissue types and in clinical trials using immune and stem cells.
In 2008, he began his professional career in Malaysia, where he made notable contributions to cancer research by integrating innovative concepts and technological improvements adapted from Japanese methodologies. With over 17 years of combined research and clinical experience, Dr. Baskar has applied innovative stem cell strategies to address medical complications that have limited conventional therapeutic options.
He has worked closely with specialists and multidisciplinary scientific teams to conduct stem cell applications using bone marrow– and umbilical cord–derived stem cells, particularly for spinal cord injuries, liver cirrhosis, and diabetic wound ulcers.
Dr. Baskar currently leads a research group collaborating with clinicians and scientists across Malaysia to evaluate outcomes of cancer immunotherapy and stem cell–based treatments for specific disorders. His research evaluations have resulted in successful publications in peer-reviewed journals.
He specializes in the production of cGMP-grade Mesenchymal Stem Cells (MSCs), Natural Killer (NK) cells, Cytotoxic T Lymphocytes (CTLs), and Dendritic Cells (DCs) in large quantities within short production timelines. The techniques developed are efficient, reproducible, and capable of yielding clinically viable cell populations.
Dr. Baskar also holds a specialized diploma in regenerative medicine from the University of Toronto. He has participated in more than 25 workshops and conferences to date and remains actively engaged in advancing his expertise.
His primary professional goal is to rejuvenate and improve life-threatening conditions through translational research, transforming innovative ideas into routine therapeutic applications, while strictly adhering to ethical principles and national regulatory guidelines.
